Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTMX CytomX Therapeutics	$0.64 +1.2%	$0.74	$0.56 ▼ $5.85	$50.93M	1.05	2.62 million shs	1.40 million shs
IMRX Immuneering	$1.52 -7.3%	$1.75	$1.00 ▼ $3.83	$54.55M	-0.32	2.36 million shs	172,602 shs
ONCY Oncolytics Biotech	$0.55 -8.3%	$0.70	$0.55 ▼ $1.53	$47.53M	1.18	513,324 shs	304,916 shs
SPRB Spruce Biosciences	$0.29 -1.7%	$0.37	$0.28 ▼ $0.87	$11.98M	2.34	481,525 shs	166,728 shs

The 10 Best Stocks to Own: Spring 2025

Discover the 10 best stocks to own in Spring 2025, carefully selected for their growth potential amid market volatility. This exclusive report highlights top companies poised to thrive in uncertain economic conditions—download now to gain an investing edge.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTMX CytomX Therapeutics	+1.21%	-5.10%	-6.11%	-38.27%	-70.83%
IMRX Immuneering	-7.32%	-12.64%	-7.88%	-30.91%	-47.40%
ONCY Oncolytics Biotech	-8.33%	-12.60%	-16.77%	-39.81%	-48.11%
SPRB Spruce Biosciences	-1.69%	-12.06%	-25.42%	-30.93%	-63.09%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CTMX CytomX Therapeutics	4.3029 of 5 stars	3.3	1.0	4.7	3.9	2.5	1.3
IMRX Immuneering	3.3173 of 5 stars	3.3	4.0	0.0	2.1	3.3	1.3
ONCY Oncolytics Biotech	1.9607 of 5 stars	3.5	3.0	0.0	3.3	0.0	0.0
SPRB Spruce Biosciences	3.1867 of 5 stars	3.0	5.0	0.0	3.0	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTMX CytomX Therapeutics	2.50	Moderate Buy	$5.02	689.95% Upside
IMRX Immuneering	2.50	Moderate Buy	$11.00	623.68% Upside
ONCY Oncolytics Biotech	3.00	Buy	$4.00	627.27% Upside
SPRB Spruce Biosciences	2.00	Hold	$2.50	761.77% Upside

Current Analyst Ratings Breakdown

Latest SPRB, IMRX, ONCY, and CTMX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/24/2025	IMRX Immuneering	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00
3/21/2025	IMRX Immuneering	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00
3/10/2025	ONCY Oncolytics Biotech	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$5.00 ➝ $3.00
3/10/2025	ONCY Oncolytics Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
3/10/2025	ONCY Oncolytics Biotech	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$6.00 ➝ $5.00
3/7/2025	CTMX CytomX Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$5.00
3/7/2025	CTMX CytomX Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
2/6/2025	IMRX Immuneering	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00
2/3/2025	ONCY Oncolytics Biotech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00 ➝ $5.00
1/13/2025	IMRX Immuneering	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
1/8/2025	IMRX Immuneering	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00

(Data available from 4/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTMX CytomX Therapeutics	$138.10M	0.37	N/A	N/A	($0.71) per share	-0.90
IMRX Immuneering	$320K	170.46	N/A	N/A	$3.09 per share	0.49
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	$0.27 per share	N/A
SPRB Spruce Biosciences	$7.10M	1.69	N/A	N/A	$1.88 per share	0.15

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTMX CytomX Therapeutics	-$570K	$0.38	3.74	N/A	N/A	10.96%	-41.47%	8.11%	5/6/2025 (Estimated)
IMRX Immuneering	-$53.47M	-$2.03	N/A	N/A	N/A	N/A	-79.19%	-69.08%	5/6/2025 (Estimated)
ONCY Oncolytics Biotech	-$20.56M	-$0.30	N/A	N/A	N/A	N/A	-141.15%	-84.73%	5/8/2025 (Estimated)
SPRB Spruce Biosciences	-$47.92M	-$0.94	N/A	N/A	N/A	-555.23%	-62.10%	-47.49%	4/2/2025 (Estimated)

Latest SPRB, IMRX, ONCY, and CTMX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
4/2/2025	N/A	SPRB Spruce Biosciences	-$0.28	-$0.22	+$0.06	N/A	$0.89 million	$0.55 million
3/20/2025	Q4 2024	IMRX Immuneering	-$0.42	-$0.58	-$0.16	-$0.58	N/A	N/A
3/6/2025	Q4 2024	CTMX CytomX Therapeutics	-$0.23	$0.22	+$0.45	$0.22	$13.53 million	$38.09 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTMX CytomX Therapeutics	N/A	N/A	N/A	N/A	N/A
IMRX Immuneering	N/A	N/A	N/A	N/A	N/A
ONCY Oncolytics Biotech	N/A	N/A	N/A	N/A	N/A
SPRB Spruce Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTMX CytomX Therapeutics	N/A	1.04	1.04
IMRX Immuneering	N/A	7.99	7.99
ONCY Oncolytics Biotech	N/A	2.99	2.99
SPRB Spruce Biosciences	0.01	5.36	5.36

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTMX CytomX Therapeutics	67.77%
IMRX Immuneering	67.65%
ONCY Oncolytics Biotech	6.82%
SPRB Spruce Biosciences	91.71%

Insider Ownership

Company	Insider Ownership
CTMX CytomX Therapeutics	7.00%
IMRX Immuneering	25.00%
ONCY Oncolytics Biotech	0.10%
SPRB Spruce Biosciences	9.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTMX CytomX Therapeutics	170	80.10 million	72.78 million	Optionable
IMRX Immuneering	60	35.89 million	23.29 million	Not Optionable
ONCY Oncolytics Biotech	30	86.42 million	85.42 million	Not Optionable
SPRB Spruce Biosciences	20	41.30 million	37.54 million	Optionable

SPRB, IMRX, ONCY, and CTMX Headlines

Recent News About These Companies

Spruce Biosciences Inc (SPRB) Stock: Understanding Its Underlying Value

February 5, 2025 | bovnews.com

Hold Rating for Spruce Biosciences Amid Clinical Setbacks and Strategic Uncertainties

December 16, 2024 | markets.businessinsider.com

Spruce Biosciences (SPRB) Upgraded to Buy: Here's Why

December 13, 2024 | zacks.com

JMP Securities Downgrades Spruce Biosciences (SPRB)

December 12, 2024 | msn.com

Spruce saws off only drug after 2nd hyperplasia fail, leaving biotech's direction in doubt

December 11, 2024 | fiercebiotech.com

Spruce Biosciences Downgraded to Hold Amid Unmet Clinical Trial Endpoints and Strategic Reevaluation

December 11, 2024 | markets.businessinsider.com

What’s Driving Spruce Biosciences Inc (SPRB) Stock’s 0.22% Surge Over the Past Month?

December 11, 2024 | bovnews.com

Oppenheimer Downgrades Spruce Biosciences (SPRB)

December 11, 2024 | msn.com

Spruce Biosciences Announces Topline Results from CAHmelia-204 in Adult CAH and CAHptain-205 in Adult and Pediatric CAH

December 11, 2024 | finance.yahoo.com

Spruce Biosciences CAHmelia-204 study did not achieve primary efficacy endpoint

December 11, 2024 | markets.businessinsider.com

JMP Securities downgrades Spruce Biosciences (SPRB) to a Hold

December 11, 2024 | markets.businessinsider.com

Spruce Biosciences downgraded to Market Perform from Outperform at JMP

December 11, 2024 | msn.com

Spruce Biosciences to wind down investment for genetic disorder drug

December 10, 2024 | reuters.com

Cautious Optimism for Tildacerfont in CAH Trials: Potential Market Opportunities and Competitive Edge Over Crinecerfont

December 6, 2024 | markets.businessinsider.com

RBC Capital Sticks to Their Hold Rating for Spruce Biosciences (SPRB)

November 13, 2024 | markets.businessinsider.com

Spruce Biosciences Faces Nasdaq Delisting Threat: Can a Reverse Stock Split Save Its Market Presence?

November 13, 2024 | markets.businessinsider.com

Spruce Biosciences Reports Q3 2024 Earnings and Updates

November 11, 2024 | tipranks.com

Spruce Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

November 11, 2024 | finanznachrichten.de

Spruce Biosciences, Inc. (SPRB) Reports Q3 Loss, Lags Revenue Estimates

November 11, 2024 | zacks.com

Spruce Biosciences, Inc. Is Being Investigated For Securities Fraud And The Schall Law Firm Urges Affected Shareholders To Reach Out

November 4, 2024 | accesswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRB, IMRX, ONCY, and CTMX Company Descriptions

CytomX Therapeutics NASDAQ:CTMX

$0.64 +0.01 (+1.21%)

Closing price 03/31/2025 04:00 PM Eastern

Extended Trading

$0.63 -0.01 (-1.54%)

As of 03/31/2025 07:26 PM Eastern

CytomX Therapeutics, Inc., an oncology-focused biopharmaceutical company, focuses on developing novel conditionally activated biologics localized to the tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increasing the therapeutic index for immune modulators, such as cytokines; and PROBODY platform in preclinical research in areas outside of oncology. It also develops CX-904, a T-cell-engaging bispecific antibody targeting the epidermal growth factor receptor (EGFR) on tumor cells and the CD3 receptor on T cells; CX-2051, a conditionally activated ADC for optimizing the therapeutic index for EpCAM-expressing epithelial cancers, including colorectal cancer; and CX-801, an interferon alpha-2b PROBODY cytokine. In addition, the company's development pipeline comprises CX-2029, a conditional activated ADC targeting CD71; and BMS-986288, a PROBODY version of non-fucosylated ipilimumab. It has strategic collaborations with Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna. CytomX Therapeutics, Inc. was founded in 2008 and is headquartered in South San Francisco, California.

Immuneering NASDAQ:IMRX

$1.52 -0.12 (-7.32%)

Closing price 03/31/2025 04:00 PM Eastern

Extended Trading

$1.63 +0.11 (+7.24%)

As of 03/31/2025 05:34 PM Eastern

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

Oncolytics Biotech NASDAQ:ONCY

$0.55 -0.05 (-8.33%)

Closing price 03/31/2025 04:00 PM Eastern

Extended Trading

$0.55 0.00 (0.00%)

As of 03/31/2025 07:51 PM Eastern

Oncolytics Biotech Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma. It has a co-development agreement with Merck KGaA and Pfizer Inc. to co-develop pelareorep, as well as with Roche Holding AG. The company was incorporated in 1998 and is headquartered in Calgary, Canada.

Spruce Biosciences NASDAQ:SPRB

$0.29 -0.01 (-1.69%)

Closing price 03/31/2025 04:00 PM Eastern

Extended Trading

$0.27 -0.02 (-6.93%)

As of 03/31/2025 07:58 PM Eastern

Spruce Biosciences, Inc., a biopharmaceutical company, focuses on developing and commercializing novel therapies for rare endocrine disorders. The company engages in developing tildacerfont, a non-steroidal therapy to enhance disease control and reduce steroid burden for patients suffering from congenital adrenal hyperplasia (CAH), which is in Phase 2b clinical trial; and to evaluate glucocorticoid reduction in adult patients with classic CAH that is Phase 2b clinical trial. It is also developing tildacerfont for the treatment of pediatric classic congenital adrenal hyperplasia in children that is in Phase 2 clinical trial; and for females with polycystic ovary syndrome, which is in Phase 2 clinical trial. Spruce Biosciences, Inc. has a license agreement with Eli Lilly and Company to research, develop, and commercialize compounds for various pharmaceutical uses; and collaboration and license agreement with Kaken Pharmaceutical Co. Ltd. to develop, manufacture, and commercialize tildacerfont for the treatment of CAH in Japan. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time